Division of Cardiology, Wonju College of Medicine, Yonsei University, Wonju, Korea and Division of Hemato-Oncology, College of Medicine, Hallym University, Chuncheon, Korea

Corresponding Author:
Jang-Young Kim ,

ABSTRACT

Anagrelide is an effective drug for essential thrombocythaemia, and its adverse cardiovascular effects are relatively rarely reported. We experienced a 73 year-old man with essential thrombocythaemia developed anagrelide-induced dilated cardiomyopathy. After discontinuation of anagrelide, the patient’s left ventricular systolic function was completely recovered.